Mbrx stock split

24 Apr 2019 We previously reported on MBRX stock in April, citing the major 1 for 5 stock reverse split earlier this month, which essentially decreased the 

MBRX Moleculin Biotech Inc. stock - Finscreener.com Moleculin Biotech Inc is a clinical-stage pharmaceutical company. The firm focus on the development of oncology drug candidates. The drug te Moleculin... (MBRX) Stock Price VWAP | Premarket | After Hours MBRX VWAP Table Volume-Weighted Average Price (VWAP) is a more comprehensive way to calculate the average price that a stock trades at over a given time frame. In the tables below, you can see minute-by-minute VWAP results for MBRX stock, as well as summarized daily values. Proposal 3. To Effect a Reverse Stock Split

Moleculin Biotech, Inc. (MBRX) Stock Analysis & News ...

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Check MBRX stock rating before trading Moleculin Biotech Inc Moleculin Biotech Inc's stock rating is based on fundamental analysis. Don't miss MBRX stock next rating changes Moleculin Biotech, Inc. (MBRX) Social Stream - Stock News

Jun 11, 2018 · On June 6, 2018, the Compensation Committee of the Board of Directors of Moleculin Biotech, Inc. (“Company”) completed its annual review of executive compensation for the 2017/2018

Whether you're looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, 

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.

Moleculin Biotech, Inc. Common Stock (MBRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Whether you're looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits,  Whether you're looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits,  7 Feb 2020 6 — one through a share purchase agreement, the other through a reverse stock split. Houston-based Moleculin Biotech Inc. (Nasdaq: MBRX),  Stock Analysis, Dividends, Split History. MBRX / Moleculin Biotech, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current  Stock Information. March 17, 2020 4:00 PM EDT NASDAQ Capital Market: MBRX. Events. Earnings. Dividends. Splits. Price. Price; % Change; $ Change.

27 Jun 2017 The second thing that is driving this stock is rooted in the potential for a reverse split. As mentioned, at the beginning of June, Moleculin was 

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas. Moleculin Biotech News, Moleculin Biotech Quote, MBRX ... May 24, 2019 05:04 AM Roth Capital Transfers Coverage on Moleculin Biotech (MBRX) at Buy May 14, 2019 07:32 AM Form 8-K Moleculin Biotech, Inc. For: May 14 MBRX | Stock Snapshot - Fidelity Apr 03, 2020 · Stock quote and company snapshot for MOLECULIN BIOTECH INC (MBRX), including profile, stock chart, recent news and events, analyst opinions, and research reports.

Jul 26, 2017 · When we last looked at Moleculin Biotech Inc (NASDAQ:MBRX), the company was down a little over 50% from late June highs and wider market sentiment surrounding the stock was decidedly negative. In our coverage, we noted that this dip in sentiment (and the concurrent dip in share price) was an opportunity to pick up shares at a discount ahead of a recovery and a longer-term upside reevaluation. Allscripts - MDRX - Stock Price & News | The Motley Fool Real time Allscripts (MDRX) stock price quote, stock graph, news & analysis. Real time Allscripts (MDRX) stock price quote, stock graph, news & analysis. The Ascent is The Motley Fool's new MBRX - Moleculin Biotech CS News - Barchart.com Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar. MBRX Moleculin Biotech Inc. stock - Finscreener.com